# Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women

> **NCT00344032** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 354 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)

## Key facts

- **NCT ID:** NCT00344032
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-28
- **Primary completion:** 2007-12-01
- **Final completion:** 2007-12-04
- **Target enrollment:** 354 (ACTUAL)
- **Last updated:** 2018-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00344032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00344032, "Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00344032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*